Lifyorli (relacorilant) — Clinical data readout
Late 2026
We expect results from our trial of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer by the end of this year.Source filing
CORT biotech catalysts & pipeline
CORCEPT THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
miricorilant — Clinical data readout
Late 2026
In addition, results from MONARCH, our Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected by the end of this year.Source filing
Lifyorli (relacorilant) — Regulatory decision
Q4 2026
In October 2025, we submitted a marketing authorization application ("MAA") to the EMA seeking approval in the EU, with an EMA decision expected in the fourth quarter of 2026.Source filing
Lifyorli (relacorilant) — PDUFA
Dec 17
We expect a decision on our NDA by December 17, 2026.Source filing
Lifyorli (relacorilant) — Regulatory decision
Dec 17
• Relacorilant for patients with Cushing's syndrome – New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026Source filing
Lifyorli (relacorilant) — Clinical data readout
Late 2027
Our studies of relacorilant to treat platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers are expected to produce results by the end of next year.Source filing
Lifyorli (relacorilant) — Clinical data readout
Late 2027
• BELLA Part C – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel in 90 patients with endometrial cancer (who have received one or two prior lines of therapy) – Results expected by the end of next yearSource filing
nenocorilant — Clinical data readout
Late 2027
Our study of nenocorilant with the PD-1 checkpoint inhibitor nivolumab to treat a variety of solid tumors will also produce results by the end of next year,Source filing